Hematological Parameters in Infection Risk

Diagnosis and Evaluation

An absolute monocyte count ≥100/μL in neutropenic patients may indicate lower risk for severe infection 1
A Complete Blood Count (CBC) with differential and peripheral blood smear examination is recommended to quantify the degree of monocytosis (>1×10⁹/L is significant) and assess monocyte morphology on peripheral smear, as suggested by the National Comprehensive Cancer Network 2, 3, 4
Inflammatory markers (ESR, CRP), liver function tests, and renal function tests can help identify underlying causes of monocytosis, as recommended by the American College of Physicians and the American Society of Hematology 5, 3
Immunophenotyping using flow cytometry can detect aberrancies in monocytic lineage, including abnormal CD11b/HLA-DR, CD36/CD14, and overexpression of CD56, as suggested by the International Society for Laboratory Hematology 6, 7
Cytogenetic analysis, including conventional karyotyping, can help detect clonal chromosomal abnormalities and exclude specific translocations, such as t(9;22) and t(5;12), as recommended by the American Society of Hematology 6

Persistent peripheral blood monocytosis >1×10⁹/L, with no Philadelphia chromosome or BCR-ABL1 fusion gene, and less than 20% blasts in peripheral blood and bone marrow, is diagnostic of CMML if at least one of the following is present: dysplasia in one or more cell lines, acquired clonal cytogenetic or molecular genetic abnormality, or persistence of monocytosis for at least 3 months with no other cause, as recommended by the World Health Organization 6

For myelodysplastic-type CMML with <10% bone marrow blasts, supportive therapy focused on correcting cytopenias, erythropoietic stimulating agents for severe anemia, and G-CSF only for severe febrile neutropenia is recommended, as suggested by the European Society for Medical Oncology 6
For myelodysplastic-type CMML with ≥10% bone marrow blasts, supportive therapy plus hypomethylating agents (5-azacytidine or decitabine), and consideration of allogeneic stem cell transplantation in selected patients within clinical trials is recommended, as suggested by the European Society for Medical Oncology 6
For myeloproliferative-type CMML with <10% blasts, cytoreductive therapy with hydroxyurea as first-line treatment to control cell proliferation and reduce organomegaly is recommended, as suggested by the European Society for Medical Oncology 6
For myeloproliferative-type CMML with high blast count, polychemotherapy followed by allogeneic stem cell transplantation when possible, or chemotherapy to maintain quality of life if transplant is not possible is recommended, as suggested by the European Society for Medical Oncology 6
The management of monocytosis involves identifying and treating the underlying cause, such as infection or inflammation, and regular CBC monitoring every 2-4 weeks initially, extending intervals if stable, as recommended by the American Society of Hematology and the European Society for Medical Oncology 6, 5

Regular complete blood count (CBC) monitoring every 2-4 weeks initially, extending intervals if stable, is recommended for CMML patients, with repeat bone marrow evaluation if cytopenias worsen or disease progression is suspected, as suggested by the European Society for Medical Oncology 6
The American Society of Clinical Oncology recommends platelet transfusions for patients with platelet counts ≤10 × 10⁹/L, for counts between 10-20 × 10⁹/L if fever/infection is present, and above 20 × 10⁹/L only for clinically relevant hemorrhage 8
Regular assessment of response and toxicity, and monitoring for disease progression or transformation is recommended, along with regular CBC monitoring and repeat bone marrow evaluation if cytopenias worsen, as suggested by the European Society for Medical Oncology 6